CCDC18 Inhibitors
CCDC18 inhibitors are chemical compounds that play a crucial role in downregulating the functional activity of CCDC18 through their effects on various cellular signaling pathways. For instance, PD 98059 and SB 203580, by inhibiting MEK and p38 MAPK respectively, create an environment that reduces cellular growth and stress responses, pathways in which CCDC18 is implicated. Similarly, LY 294002 and Rapamycin target the PI3K/Akt and mTOR pathways, which are pivotal for cell survival and proliferation, processes that are essential for the proper activity of CCDC18. Bortezomib, through proteasome inhibition, disrupts protein degradation mechanisms, leading to a decrease in CCDC18 activity which is reliant on protein turnover. In contrast, WZB117 limits energy supply by inhibiting GLUT1, suggesting that the energy-intensive processes governed by CCDC18 are indirectly curtailed.
The impact of these inhibitors extends to cell cycle regulation, with compounds like PD 0332991 halting the progression from G1 to S phase, thus causing areduction in the regulatory influence of CCDC18 on cell division. Triciribine and SP600125 add to this inhibitory arsenal by targeting Akt and JNK pathways, respectively, which are crucial for the survival and proliferation of cells, and possibly for the functional efficacy of CCDC18. The influence of Sunitinib and Sorafenib stretches to angiogenesis and cell migration, where CCDC18 might play a role; by attenuating receptor tyrosine kinase and RAF/MEK/ERK signaling, these inhibitors can indirectly limit the functional terrain of CCDC18. Lastly, Gefitinib's impairment of EGFR signaling further contributes to the spectrum of inhibition, encapsulating the multifaceted approach required to diminish the activity of CCDC18, which is likely implicated in a variety of cellular processes, including cell proliferation and survival. Collectively, these inhibitors work synergistically to curtail the functional activity of CCDC18, providing insight into the complex regulation of cellular mechanisms where CCDC18 is involved.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
This is a MEK inhibitor that indirectly diminishes the MAPK/ERK pathway. Since CCDC18 is associated with cellular division and growth, reduced MAPK/ERK signaling can lead to a decrease in cellular proliferation processes that CCDC18 is involved in, resulting in a lowered functional activity of CCDC18. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A PI3K inhibitor that leads to the attenuation of the PI3K/Akt signaling pathway. Given that CCDC18 plays a role in cell growth and survival, the inhibition of this pathway leads to decreased survival signals, indirectly diminishing the cellular environment in which CCDC18 functions. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor that leads to the downregulation of the mTOR signaling pathway. Since mTOR is involved in the regulation of cell growth and proliferation, inhibiting this pathway can indirectly decrease CCDC18 functional activity by reducing the cellular processes it regulates. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
This compound is a p38 MAPK inhibitor, which dampens the response to stress stimuli in cells. As stress responses can modulate cellular growth, inhibiting this pathway can result in the indirect diminishment of CCDC18 activity associated with these processes. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
A proteasome inhibitor that leads to accumulation of misfolded proteins, inducing cell cycle arrest and apoptosis. CCDC18 function is dependent on the regulated degradation of proteins; thus, inhibiting the proteasome can indirectly diminish CCDC18 activity. | ||||||
Wiskostatin | 253449-04-6 | sc-204399 sc-204399A sc-204399B sc-204399C | 1 mg 5 mg 25 mg 50 mg | $49.00 $124.00 $441.00 $828.00 | 4 | |
A GLUT1 inhibitor that can reduce glucose uptake in cells. Since CCDC18 is involved in processes that are energy-dependent, reducing glucose availability can indirectly diminish the functional activity of CCDC18 by limiting energy resources. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
A CDK4/6 inhibitor that blocks cell cycle progression from G1 to S phase. CCDC18, being involved in cell cycle regulation, would have diminished functional activity as a result of the inhibition of cell cycle progression. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $104.00 $141.00 | 14 | |
An Akt inhibitor that can decrease the signaling through the PI3K/Akt pathway. By inhibiting Akt, the downstream effects that CCDC18 may have on cell survival and growth are indirectly diminished. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of JNK, which is involved in controlling apoptosis and cell proliferation. Inhibition of JNK signaling can lead to decreased activity of CCDC18 if it is involved in cell survival pathways influenced by JNK. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
A receptor tyrosine kinase inhibitor that can affect various signaling pathways including VEGF and PDGF signaling. By inhibiting these pathways, it can indirectly diminish the functional activity of CCDC18 in angiogenesis and cell migration. | ||||||